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FIRST PARAGRAPH 
Metastatic disease remains the primary cause of death for breast cancer patients. The 
different steps of the metastatic cascade rely on reciprocal interactions between cancer cells 
and their microenvironment. Within this local microenvironment and in distant organs, 
immune cells and their mediators are known to facilitate metastasis formation1,2. However, 
the precise contribution of tumor-induced systemic inflammation to metastasis and the 
mechanisms regulating systemic inflammation are poorly understood. Here, we show that 
tumors maximize their chance to metastasize by evoking a systemic inflammatory cascade in 
mouse models of spontaneous breast cancer metastasis. We mechanistically demonstrate 
that IL1β elicits IL17 expression from γδ T cells, resulting in systemic, G-CSF-dependent 
expansion and polarization of neutrophils in mammary tumor-bearing mice. Tumor-induced 
neutrophils acquired the ability to suppress cytotoxic CD8+ T lymphocytes, which limit the 
establishment of metastases. Neutralization of IL17 or G-CSF and absence of γδ T cells 
prevented neutrophil accumulation and down-regulated the T cell-suppressive phenotype of 
neutrophils. Moreover, the absence of γδ T cells or neutrophils profoundly reduced 
pulmonary and lymph node metastases without influencing primary tumor progression. Our 
data indicate that targeting this novel cancer cell-initiated domino effect within the immune 
system – the γδ T cell-IL17-neutrophil axis – represents a new strategy to inhibit metastatic 
disease. 
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MAIN TEXT 
In breast cancer patients, increased neutrophil abundance predicts worsened metastasis-
specific survival3,4. Currently, the role of neutrophils in metastasis is controversial, since both 
pro- and anti-metastatic functions have been described5-7. We found a profound systemic 
expansion of neutrophils in mammary tumor-bearing K14cre;Cdh1F/F;Trp53F/F (KEP) mice8, 
as compared to wild-type (WT) littermates (Extended Data Fig. 1a, b). Neutrophils, defined 
as CD45+CD11b+Ly6G+Ly6C+F4/80— cells, accumulated throughout every organ examined 
(Extended Data Fig. 1c, d). We also investigated our recently described KEP-based model 
of spontaneous breast cancer metastasis9 (Fig. 1a), where systemic neutrophil expansion 
was observed as well (Fig. 1b and Extended Data Fig. 1e, f). Neutrophil expansion was 
tumor-induced, because surgical removal of the primary tumor resulted in their immediate 
reduction (Extended Data Fig. 1g).  
To determine the functional significance of neutrophils in metastasis, neutrophils were 
depleted using anti-Ly6G antibodies (Extended Data Fig. 2a-c). Treatment was initiated 
when tumors were palpable and continued until mice developed overt metastatic disease. 
Neutrophil depletion did not influence tumor growth (Extended Data Fig. 2d), tumor 
histopathology (Extended Data Fig. 2e) or microvessel density (Extended Data Fig. 2e, f). 
By contrast, neutrophil depletion resulted in significant reduction in both pulmonary and 
lymph node metastasis (Fig. 1c). These data indicate that neutrophils assist the spread of 
cancer cells to multiple locations.  
Next, we evaluated the role of neutrophils in different phases of the metastatic 
cascade. Neutrophils were depleted during primary tumor growth (early phase) or after 
removal of the primary tumor (late phase) (Fig. 1a). Interestingly, neutrophil depletion 
decreased multi-organ metastasis in the early phase, but not the late phase (Fig. 1d). 
Metastatic nodule size was not affected (Extended Data Fig. 2g), suggesting that 
neutrophils facilitate multi-organ metastasis during the early steps of the metastatic cascade.  
To understand the mechanism by which neutrophils facilitate metastasis, their 
phenotype was investigated. Previous reports identified the hematopoietic stem cell marker, 
cKIT, on pro-metastatic myeloid cells6,10-12, and CD11b+VEGFR1+ cells have been implicated 
in the pre-metastatic niche10,13,14. A greater proportion of neutrophils from tumor-bearing KEP 
mice expressed cKIT, while both neutrophils and monocytes from WT and KEP mice 
expressed VEGFR1 (Extended Data Fig. 3a, b). In the metastasis model, cKIT+ neutrophils 
also expanded systemically, as tumors grew larger (Extended Data Fig. 3c) and reduced to 
baseline levels after tumor resection (Extended Data Fig. 3d). Nuclear morphological 
analysis revealed characteristics of immature cells15, including banded, circular and non-
segmented nuclei, whereas most WT neutrophils appeared hyper-segmented (Extended 
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Data Fig. 3e), suggesting that KEP mammary tumors promote the release of immature 
neutrophils into circulation. 
Next generation sequencing (RNA-seq) was performed on circulating neutrophils 
from WT and tumor-bearing KEP mice, revealing 100 differentially expressed genes 
(Extended Data Fig. 4a and Extended Data Table 1). Several genes upregulated in 
neutrophils from KEP mice, including Prok2/Bv8, S100a8 and S100a9 (Fig. 2a), have 
previously been linked to metastasis6,14. Nos2, the gene encoding inducible nitric oxide 
synthase (iNOS), was the most strongly upregulated gene by more than 150-fold (Fig. 2a). 
Because iNOS suppresses T cells16-18, we hypothesized that neutrophils promote metastasis 
via immunosuppression. Indeed, neutrophils from KEP mice inhibited the CD3/CD28-induced 
proliferation of naïve splenic CD8+ T cells ex vivo when compared with WT neutrophils, and 
an iNOS inhibitor reversed this effect (Fig. 2b and Extended Data Fig. 4b). In lungs of 
control and neutrophil-depleted tumor-bearing mice, the proportions of CD8+ T cells did not 
differ (Extended Data Fig. 4c). However, the effector phenotype of CD8+ T cells was 
markedly enhanced upon neutrophil depletion, as evidenced by a significantly greater 
proportion of CD62L—CD44+ and IFNγ+ cells (Fig. 2c and Extended Data Fig. 4d, e). To 
further establish a mechanistic link between neutrophils and CD8+ T cell activity, we depleted 
both cell populations in the metastasis model. Combined depletion of neutrophils and CD8+ T 
cells reversed the metastasis phenotype of neutrophil depletion alone (Fig. 2d), without 
affecting primary tumor growth (Extended Data Fig. 4f). Depletion of CD8+ T cells alone did 
not alter tumor growth or multi-organ metastasis (data not shown). These data suggest that 
neutrophils facilitate cancer cell spread by suppressing CD8+ T cells. As such, neutrophils in 
the KEP model can be categorized as a subpopulation of myeloid-derived suppressor cells 
(MDSCs)15. 
We then asked how mammary tumors induce systemic neutrophil expansion. 
Cytokine profile comparison of WT mammary glands and KEP mammary tumors showed that 
GM-CSF and G-CSF levels – two key regulators of neutrophil biology19 – were not 
significantly increased in KEP tumors (Extended Data Fig. 5a, b). However, expression of 
IL1β, IL6, and IL12p40, a subunit of IL23, was increased (Extended Data Fig. 5a, b). These 
cytokines are known to stimulate IL17 from lymphocytes20-23. In inflammatory diseases such 
as psoriasis, lymphocyte-derived IL17 regulates neutrophil expansion via systemic induction 
of G-CSF21,22,24. We hypothesized that the same inflammatory cascade is important in breast 
cancer metastasis. Indeed, serum levels of IL17A and G-CSF were higher in tumor-bearing 
KEP mice than in WT mice (Fig. 3a). Neutralization of IL17A in tumor-bearing KEP mice 
decreased G-CSF serum levels, while G-CSF blockade did not affect IL17A levels (Fig. 3a), 
indicating that IL17 is upstream of G-CSF. Inhibition of either cytokine reduced circulating 
neutrophils, lowered cKIT+ neutrophil proportions (Fig. 3b) and reversed neutrophil 
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phenotype (Fig. 3c). Injection of recombinant G-CSF to anti-IL17-treated tumor-bearing KEP 
mice overcame the effects of anti-IL17 treatment (Extended Data Fig. 5c-e). Additionally, 
treatment of WT mice with recombinant G-CSF resulted in neutrophil expansion, increased 
presence of cKIT+ neutrophil proportions, and changed neutrophil phenotype (Extended 
Data Fig. 5c-e). These data demonstrate a requirement for the IL17-G-CSF signaling 
cascade in both neutrophil expansion and phenotype. 
Next, we determined the source of IL17. As T cells are known to produce IL1720,21,23, 
splenic CD3+ T cells were analyzed using a T cell-specific gene expression array. This 
analysis validated upregulation of IL17-related cytokines in T cells from tumor-bearing KEP 
mice (Extended Data Fig. 5f). We then asked whether lymphocytes are the only source of 
IL17 and whether they drive metastasis. KEP mice were crossed with Rag1—/— mice, which 
lack T and B cells. Tumor initiation, proliferation and histology were the same between 
KEP;Rag1+/— and KEP;Rag1—/— mice (Extended Data Fig. 6a and data not shown). 
However, KEP;Rag1—/— mice exhibited lower levels of IL17A and G-CSF in serum (Fig. 3d), 
decreased neutrophil counts (Fig. 3e) and altered neutrophil phenotype (Fig. 3f). TGFβ1 
levels were unchanged between KEP;Rag1+/— and KEP;Rag1—/— mice (Extended Data Fig. 
6b), suggesting that unlike other models25, TGFβ plays a lesser role in modulating neutrophil 
phenotype than IL17-induced G-CSF. Importantly, KEP;Rag1—/— mice displayed less 
pulmonary and lymph node metastases (Fig. 3g). The metastasis phenotype in KEP;Rag1—
/— mice was validated in the metastasis model where Rag1—/— mice were recipients of 
transplanted KEP tumor fragments, resulting in reduced pulmonary metastasis (Extended 
Data Fig. 6c). Thus, IL17-producing lymphocytes drive neutrophil accumulation, phenotype 
and metastasis.  
Direct ex vivo intracellular cytokine staining was performed to determine which T 
lymphocyte subset produces IL17. Both CD4+ T cells and γδ T cells expressed IL17A (Fig. 
4a), and both IL17-producing subpopulations were increased in various organs of tumor-
bearing KEP mice when compared to WT mice (Fig. 4b and Extended Data Fig. 7a). In 
primary tumors, the abundance of γδ and CD4+ T cells was too low (<0.2% and <2% of all 
live cells, respectively) to reliably assess IL17 expression. γδ T cells exhibited higher IL17A 
levels than CD4+ T cells (Fig. 4a and Extended Data Fig. 7b). Both cell populations were 
depleted to determine their functional importance. CD4+ T cell depletion lowered cKIT+ 
neutrophils, but failed to significantly influence total neutrophil expansion, IL17A or G-CSF 
levels (Extended Data Fig. 7c-e). Conversely, depletion of γδ T cells decreased IL17A and 
G-CSF serum levels (Fig. 4c), reduced circulating neutrophils, lowered cKIT+ neutrophil 
proportions (Fig. 4d and Extended Data Fig. 7c) and reversed neutrophil phenotype (Fig. 
4e). These data indicate that IL17-producing γδ T cells promote neutrophil expansion and 
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phenotypic alterations. IL17-producing γδ T cells in tumor-bearing KEP mice were CD27—, 
mostly Vγ4+, and a proportion expressed CCR6, IL1R1 and RORγt (Extended Data Fig. 8a, 
b) similar to other inflammatory diseases21.  
We then asked how KEP mammary tumors activate IL17-producing γδ T cells. Based 
on literature20-23 and cytokine analysis (Extended Data Fig. 5a, b), we focused on IL23 and 
IL1β. IL17A expression by γδ T cells, G-CSF serum levels and neutrophil expansion was 
decreased by neutralization of IL1β, but unaffected by inhibition of IL23 (Fig. 4f-h). 
Macrophages were the most abundant IL1β-expressing cell type in KEP tumors (Extended 
Data Fig. 8c, d). These data provide a mechanistic link between mammary tumors and γδ T 
cells. 
Depletion of γδ T cells in the early phase of the metastasis model did not affect tumor 
histopathology, microvessel density, or primary tumor growth (Extended Data Fig. 8e and 
data not shown). Importantly, however, pulmonary and lymph node metastasis were 
significantly decreased in γδ T cell-depleted mice (Fig. 4i). These data were validated with 
Tcrδ—/— mice, which lack γδ T cells. KEP tumor fragments were orthotopically transplanted 
into Tcrδ+/— and Tcrδ—/— mice and resected following outgrowth. Genetic elimination of γδ T 
cells also resulted in a significant reduction in pulmonary metastasis (Fig. 4j) without 
affecting primary tumor growth (Extended Data Fig. 8f). These data confirmed a pro-
metastatic role for γδ T cells. 
In summary, we show that mammary tumor-induced, IL17-producing γδ T cells drive 
systemic expansion and polarization of neutrophils towards a CD8+ T cell-suppressive 
phenotype and subsequent metastasis formation in distant organs (Extended Data Fig. 9). 
The importance of neutrophils during the early steps of the metastatic cascade and the 
upregulation of Bv8/Prok2, S100a8 and S100a9 in neutrophils suggest that neutrophils may 
help to establish the pre-metastatic niche6,10,14; although, the role of these neutrophil-derived 
factors and others remains to be established in the KEP model. In breast cancer patients, 
independent clinical studies consistently point towards a pro-metastatic role for neutrophils, 
γδ T cells and IL173,4,26-29. Here, we establish a mechanistic connection between these 
independent clinical observations. In infection and inflammatory disorders, the γδ T cell-IL17-
neutrophil axis drives disease pathogenesis21,23,30. We now demonstrate that this targetable 
pathway also perpetuates breast cancer metastasis. 
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FIGURE LEGENDS 
Figure 1. Neutrophils promote breast cancer metastasis. a, Spontaneous metastasis 
model. Tumor fragments from KEP mice are orthotopically transplanted into WT recipient 
mice (designated by #1), allowed to proliferate (#2), then surgically resected (#3)9. 
Metastases develop in 100% of recipient mice. Antibody-mediated depletion experiments 
were performed in three ways: from palpable tumors to metastasis-related sacrifice 
(continuous treatment), during primary tumor growth (early phase), or after surgery until 
metastasis-related sacrifice (late phase). b, Neutrophil proportions in lungs at the indicated 
tumor size (n = 6, 5, 6 and 8 mice for 0, 9, 25 and 100 mm2, respectively; Kruskal–Wallis test 
followed by Dunn’s post test). c, d, Images of cytokeratin 8-stained lung sections, 
quantification of lung metastases and incidence of metastasis in lymph nodes. Neutrophils 
were depleted continuously until metastasis-related sacrifice in c (n = 11 mice/group; Mann-
Whitney U test and Fisher’s exact test) or depleted during the early or late phases in d (n = 9 
control, 11 early phase, 14 late phase; Kruskal–Wallis test followed by Dunn’s post test and 
Fisher’s exact test). Data in d are representative of two independent experiments. All data 
are mean + s.e.m. *p<0.05, **p<0.01, ***p<0.001. Scale bars = 6 mm. 
 
Figure 2. Neutrophils suppress CD8+ T cell activation to facilitate metastasis. a, Gene 
expression in circulating neutrophils (n = 5 WT, 10 KEP mice). b, Circulating neutrophils from 
either WT (n = 7) or tumor-bearing KEP mice (n = 8) were incubated with CFSE-labeled 
splenic CD8+ T cells from WT mice and CD3/CD28 stimulation beads. The iNOS inhibitor, L-
NMMA, was added where indicated (n = 8). After 48 hours, CD8+ T cell proliferation was 
measured. c, CD8+ T cell activation status in lungs of transplanted tumor-bearing control and 
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neutrophil-depleted mice (n = 6/group). d, Quantification of lung metastases and incidence of 
lymph node metastasis following neutrophil and CD8+ T cell depletion (n = 11 control, 16 
anti-Ly6G, 8 anti-Ly6G/CD8; Kruskal–Wallis test followed by Dunn’s post test and Fisher’s 
exact test). All data are mean + s.e.m. *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 3. Lymphocyte-derived IL17 is required for G-CSF-induced neutrophil 
expansion and phenotype. a, Cytokine levels in serum of WT (n = 5), tumor-bearing KEP 
mice (n = 9), and anti-IL17- (n = 7) or anti-G-CSF-treated KEP mice (n = 6). b, Proportions of 
circulating neutrophils and cKIT-expressing neutrophils in KEP mice during primary tumor 
growth (n = 9 control, 8 anti-IL17, 6 anti-G-CSF). c, Gene expression in circulating 
neutrophils from tumor-bearing KEP control mice (n = 9), anti-IL17- (n = 6) or anti-G-CSF-
treated KEP mice (n = 6). d, Cytokine levels in serum of tumor-bearing KEP;Rag1+/— (n = 9) 
and KEP;Rag1—/— mice (n = 7). e, Absolute blood neutrophil counts in tumor-bearing 
KEP;Rag1+/— mice (n = 8) or KEP;Rag1—/— mice (n = 5). f, Gene expression in circulating 
neutrophils from KEP;Rag1+/— (n = 10) and KEP;Rag1—/— mice (n = 8). g, Percentage of 
tumor-bearing mice with lung or lymph node metastasis (n = 50 KEP;Rag1+/—, 32 
KEP;Rag1—/— mice). All data are mean + s.e.m. *p<0.05, **p<0.01, ***p<0.001 as 
determined by Mann-Whitney U test or Fisher’s exact test.  
 
Figure 4. IL1β-activated, IL17-producing γδ T cells regulate neutrophil expansion, 
neutrophil phenotype and metastasis. a, Intracellular staining within circulating T cells of 
tumor-bearing KEP mice. b, Proportion of IL17A-producing γδ T cells (WT, n = 5; KEP, n = 6). 
c, Cytokine levels in serum of control (n = 10) and anti-γδTCR-treated (n = 7) KEP mice. d, 
Proportions of circulating neutrophils and cKIT-expressing neutrophils in KEP mice during 
primary tumor growth (n = 8/group). e, Gene expression in circulating neutrophils from tumor-
bearing KEP control mice (n = 10) and anti-γδTCR-treated KEP mice (n = 6). f, Proportion of 
IL17A-producing γδ T cells in tumor-bearing mice (n = 6 KEP control, 5 anti-IL23p19, 5 anti-
IL1β). g, Cytokine levels in serum (n = 9 KEP control, 5 anti-IL23p19, 6 anti-IL1β). h, 
Proportions of circulating neutrophils and cKIT-expressing neutrophils in KEP mice during 
primary tumor growth (n = 9 control, 5 anti-IL23p19, 5 anti-IL1β). i, j, Quantification of lung 
metastases and incidence of lymph node metastasis in the metastasis model (n = 10 control, 
9 anti-γδTCR-treated mice; n = 9/group Tcrδ+/— and Tcrδ—/— mice,). All data are mean + s.e.m. 
*p<0.05, **p<0.01, ***p<0.001 as determined by Mann-Whitney U test or Fisher’s exact test.  
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METHODS  
Mice 
The generation and characterization of K14cre;CdhF/F;Trp53F/F (KEP) mice – a conditional 
model of invasive lobular breast cancer – has been described8. KEP mice were back-crossed 
onto the FVB/N background. KEP mice were crossed with Rag1—/— mice (FVB/N; a gift from 
L. Coussens)32 to generate KEP;Rag1+/— and KEP;Rag1—/— mice33.  The onset of mammary 
tumor formation was monitored twice weekly by palpation and caliper measurements starting 
at four months of age. Tcrδ—/— mice on the FVB/N background were a gift from A. Hayday34. 
The spontaneous metastasis model has also been described9. Briefly, this model is based on 
the orthotopic transplantation of KEP tumor pieces into 10-12 week old female recipient 
FVB/N mice, Rag1—/— mice, Tcrδ+/— or Tcrδ—/— mice. These tumor pieces are allowed to grow 
out, then surgically removed at 100 mm2, after which 100% of mice develop overt metastatic 
disease. 
To deplete immune cells or neutralize cytokines, mice were injected i.p. with an initial 
400 µg followed by 100 µg thrice weekly for anti-Ly6G (clone 1A8; BioXCell), 200 µg twice 
weekly for anti-CD8 (clone 2.43; BioXCell), or 100 µg twice weekly for anti-γδTCR (clone 
GL3; purified by the NKI protein facility). For cytokine neutralization experiments, KEP mice 
were injected i.p. with 50 µg twice weekly for anti-IL17A (clone 17F3; BioXCell), 50 µg thrice 
weekly for anti-G-CSF (clone 67604; R&D Systems), 50 µg twice weekly anti-IL23p19 (clone 
G23-8; eBioscience), or 50 µg twice weekly anti-IL1β (clone B122; BioXCell). Control mice 
received equal amounts of isotope control antibodies or equal volumes of PBS. Where 
indicated, WT and KEP mice were injected i.p. with 5 µg rG-CSF (Peprotech) for 4 
consecutive days and were sacrificed on the 5th day. Tumor-bearing KEP mice injected with 
rG-CSF received anti-IL17 at the same schedule as above. Antibody injections began when 
K14cre;CdhF/F;Trp53F/F mammary tumors reached 25 mm2 until sacrifice at 225 mm2, or 
transplanted tumors reached 9 mm2 where indicated until surgery at 100 mm2. Three 
independent K14cre;CdhF/F;Trp53F/F donor tumors were tested in neutrophil depletion 
experiments resulting in the same outcome. One of these donor tumors was used throughout 
the remainder of the study. Blood samples were taken before and during antibody injections 
for flow cytometry analyses. Animals were randomized before beginning the treatment 
schedule. Mice were kept in individually ventilated and open cages and food and water were 
provided ad libitum. Animal experiments were approved by the Animal Ethics Committee of 
the Netherlands Cancer Institute and performed in accordance with institutional, national and 
European guidelines for Animal Care and Use. 
 
Immunohistochemistry 
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Formalin-fixed tissues were processed by routine procedures. H&E staining was performed 
as described9. Citrate antigen retrieval was used for all staining procedures. Neutrophils 
were detected using either anti-Ly6B (clone 7/4; Cedarlane) or anti-Ly6G (clone 1A8; BD 
Biosciences), when primary tumors reached 100 mm2. Quantitative analysis of neutrophil 
abundance was performed by counting cells in 5 high-power (40X) fields of view (FOV) per 
tissue. Metastases were detected using anti-cytokeratin 8 (clone Troma 1; DHSB University 
of Iowa). In the metastasis model, the total number of cytokeratin 8+ nodules was scored in 
one lung section of each animal. The size of each nodule was measured using ImageJ, then 
represented as arbitrary units. Lymph node metastases were scored as positive or negative 
based on the presence of cytokeratin 8+ metastases. Mice that developed overt metastatic 
disease (i.e. respiratory distress or 225 mm2 axillary lymph node metastasis) were included 
in the analysis; mice that were sacrificed as a result of local recurrence were excluded. 
Vimentin, E-cadherin and CD34 staining was performed as previously described9 and scored 
independently by two blinded researchers. Microvessel density was scored by averaging the 
total number of blood vessels from 5 fields of view for each tumor section. For metastasis 
quantification in K14cre;CdhF/F;Trp53F/F;Rag1+/— and K14cre;CdhF/F;Trp53F/F;Rag1—/— mice, 
single lung or lymph node sections were scored as positive or negative based on the 
presence of cytokeratin 8+ metastases. Stained slides were digitally processed using the 
Aperio ScanScope and captured using ImageScope software version 11.0.2. Brightness and 
contrast for representative images were adjusted equally among groups. 
 
Flow cytometry and intracellular staining 
Tissues were collected in ice-cold PBS. Blood samples were collected in tubes containing 
heparin. Tumors and lungs were mechanically chopped using a McIlwain tissue chopper 
(Mickle Laboratory Engineering Co.). Tumors were digested for 1 hour at 37 °C in 3 mg/mL 
collagenase type A (Roche) and 25 µg/mL DNAse (Sigma) in serum-free DMEM medium. 
Lungs were digested for 30 minutes at 37 °C in 100 µg/mL Liberase TM (Roche). Enzyme 
activity was neutralized by addition of cold DMEM/8% FCS and suspension was dispersed 
through a 70 µm cell strainer. Spleen, lymph nodes and liver were mashed through a 70 µm 
cell strainer. All single cell suspensions were treated with NH4Cl
 erythrocyte lysis buffer. Cells 
were stained with directly conjugated antibodies (listed below) for 30 minutes at 4 °C in the 
dark in PBS/1% BSA. 7AAD (1:20; eBioscience) or Fixable Viability Dye eFluor® 780 
(1:1000; eBioscience) was added to exclude dead cells. For intracellular staining, single cell 
suspensions were stimulated in IMDM containing 8% FCS, 100 IU/mL penicillin, 100 µg/mL 
streptomycin, 0.5% ² -mercaptoethanol, 50 ng/mL PMA, 1 µM ionomycin and (1:1000) Golgi-
Plug™ (BD Biosciences) for 3 hours at 37 °C. Surface antigens were stained first, followed 
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by fixation and permeabilization using the Cytofix/Cytoperm™ kit (BD Biosciences) and 
followed by staining of intracellular proteins. All experiments were performed using a BD 
LSRII flow cytometer using Diva software. Data analyses were performed using FlowJo 
Software version 9.7.1. Median fluorescence intensity (MFI) of IL17A expression was 
calculated after gating on IL17+ cells within individual T cell subsets. 
 All antibodies were purchased from eBioscience, except Ly6G-AlexaFluor 700, CCR6 
and Vγ1 from BioLegend, and VEGFR1, CCR2, IL23R and IL1R1 from R&D Systems. The 
following antibodies were used in these experiments:  
Myeloid panel – CD45-eFluor 605NC (1:50; clone 30-F11), CD11b-eFluor 650NC (1:400; 
clone M1/70), Ly6G-AlexaFluor 700 (1:400; clone 1A8), Ly6C-eFluor 450 (1:400; clone 
HK1.4), F4/80-APC-eFluor 780 (1:200; clone BM8), VEGFR1-APC (1:50; clone 141522), 
cKIT (1:400; clone 2B8), CCR2-PE (1:50; clone 475301), CXCR4-PerCP-eFluor 710 (1:400; 
clone 2B11), CD49d-FITC (1:400; clone R1-2) or Gr1-FITC (1:400; clone RB6-8C5), 7AAD. 
 
Lymphoid panel I – CD45-eFluor 605NC (1:50; clone 30-F11), CD11b-eFluor 650NC (1:400; 
clone M1/70), CD3-PE-Cy7 (1:200; clone 145-2C11), CD4-APC-eFluor 780 (1:200; clone 
GK1.5), CD8-PerCP-eFluor 710 (1:400; clone 53-6.7), γδTCR-FITC (1:400; clone GL3), 
CD49b-APC (1:400; clone DX5), IL17A-PE (1:200; clone eBio17B7), IFNγ-eFluor 450 (1:200; 
clone XMG1.2), 7AAD. 
 
Lymphoid panel II – CD45-eFluor 605NC (1:50; clone 30-F11), CD11b-APC-eFluor 780 
(1:200; clone M1/70), CD3-PE-Cy7 (1:200; clone 145-2C11), CD4-APC-eFluor 780 (1:200; 
clone GK1.5), CD8-PerCP-eFluor 710 (1:400; clone 53-6.7), γδTCR-PE (1:400; clone GL3), 
CD49b-APC (1:400; clone DX5), CD62L-AlexaFluor 700 (1:400; clone MEL-14), CD44-FITC 
(1:400; clone IM7), IFNγ-eFluor 450 (1:200; clone XMG1.2), CD19-APC-eFluor 780 (1:200; 
clone eBio1D3), Fixable Viability Dye eFluor® 780. 
 
γδ T cell phenotyping panel I – CD45-eFluor 605NC (1:50; clone 30-F11), CD11b-APC-
eFluor 780 (1:200; clone M1/70), CD3-PerCP-eFluor 710 (1:200; clone 145-2C11), CD4-
APC-eFluor 780 (1:200; clone GK1.5), γδTCR-PE (1:400; clone GL3), CD19-APC-eFluor 780 
(1:200; clone eBio1D3), CD27-PE-Cy7 (1:200; clone LG.7F9), IL1R1-FITC (1:25; clone 
129304), CCR6-Brillant Violet 421 (1:200: clone 29-2L17), IL23R-AlexaFluor 700 (1:25; clone 
753317), RORγt-APC (1:100; clone B2D), Fixable Viability Dye eFluor® 780. 
 
γδ T cell phenotyping panel II – CD45-eFluor 605NC (1:50; clone 30-F11), CD11b-APC-
eFluor 780 (1:200; clone M1/70), CD4-APC-eFluor 780 (1:200; clone GK1.5), γδTCR-PE 
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(1:400; clone GL3), CD19-APC-eFluor 780 (1:200; clone eBio1D3), CD27-PE-Cy7 (1:200; 
clone LG.7F9), Vγ1-FITC (1:100; clone 2.11), Vγ4-PerCP-eFluor 710 (1:100; clone UC3-
10A6), IFNγ-eFluor 450 (1:200; clone XMG1.2), IL17A-APC (1:200; clone eBio17B7), Fixable 
Viability Dye eFluor® 780. 
 
White blood cell counts 
Total white blood cell numbers were measured on a hematology analyzer (Becton Dickinson). 
Neutrophil numbers were then calculated based on the percentage of CD11b+Ly6G+Ly6C+ 
cells. 
 
Giemsa Staining 
Blood was collected by tail vein puncture in heparin-coated tubes. Red blood cells were lysed 
with NH4Cl
 lysis buffer. White blood cells were smeared onto glass slides then stained with 
decreasing concentrations of Wright-Giemsa solution. 
 
RNA-Seq and gene ontology analysis 
Ly6G+ neutrophils were isolated by magnetic column (Miltenyi) from blood of mice. KEP mice 
with mammary tumors around 225 mm2 in size and age-matched WT mice were used. Purity 
of isolated neutrophils was validated by flow cytometry and only samples greater than 90% 
purity were used. RNA was isolated using Trizol and then treated with DNase I (Invitrogen). 
Samples were put over a Qiagen RNeasy column for cleanup. RNA quality was confirmed 
with a 2100 Bioanalyzer from Agilent. RNA-Seq libraries were prepared using the reagents 
provided in the Illumina TruSeq™ RNA Sample Preparation Kit, following the manufacturer’s 
protocol. Libraries were PCR amplified for 12 cycles and sequenced on an Illumina HiSeq 
2000 System with TruSeq reagent kits and software, generating 51bp reads. Sequence 
reads were aligned to the mouse reference genome (NCBI build 37) using TopHat. HTSeq-
count was then used to generate a list of the total number of uniquely mapped reads for each 
gene and sample. Sequence reads were normalized to 10 million reads per sample and log2 
transformed with the formula, log2(((expression gene X ÷ library size)106)+1), where the 
library size was the sum of all expression values per sample. In order to determine which 
genes were differentially expressed between samples, the R package Limma was used. 
Absolute gene expressions were used as input and genes with no expression in any sample 
were removed from the dataset. Voom was used to transform the count data to log2 counts 
per million and estimation of the variance. The p value was set to a cut-off of 0.05 resulting in 
100 significant, differentially expressed genes. Unsupervised clustering was performed on 
these 100 genes and the data were transformed into a heat-map. 
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Real-time PCR 
Neutrophil RNA was extracted as above then converted to cDNA with an AMV reverse 
transcriptase using Oligo(dT) primers (Invitrogen). cDNA (20 ng/well) was analyzed by SYBR 
green real-time PCR with 500 nM primers using a LightCycler® 480 thermocycler (Roche). β-
actin was used as a reference gene. The following primer sequences were used for each 
gene: Nos2 forward 5’-GTTCTCAGCCCAACAATACAAGA-3’, reverse 5’-
GTGGACGGGTCGATGTCAC-3’; Prok2/Bv8 forward 5’- CTTCGCCCTTCTTCTTTCCT-3’, 
reverse 5’- GCATGTGCTGTGCTGTCAGT-3’; S100a8 forward 5’- 
TGAGCAACCTCATTGATGTCTACC-3’, reverse 5’-ATGCCACACCCACTTTTATCACC-3’; 
S100a9 forward 5’- GAAGAAAGAGAAGAGAAATGAAGCC-3’; reverse 5’- 
CTTTGCCATCAGCATCATACACTCC-3’; Il1β forward 5’- 
CAACCAACAAGTGATATTCTCCATG-3’, reverse 5’-GATCCACACTCTCCAGCTGCA -3’; β-
actin forward 5’-CCTCATGAAGATCCTGACCGA-3’, reverse 5’- 
TTTGATGTCACGCACGATTTC-3’. Fold change was calculated using the formula 2^-(∆Ct -
[∆CtWT]). 
 
T cell proliferation assay 
Blood neutrophils from WT mice and splenic CD8+ T cells from WT mice were isolated by 
magnetic column (Miltenyi). Blood neutrophils from KEP mice with mammary tumors around 
225 mm2 in size were also used. CD8+ T cells were labeled with Cell Trace CFSE following 
the manufacturer’s instructions (Invitrogen). Equal numbers of cells (2x105) were co-cultured 
in a 96-well flat bottom plate. CD3/CD28 Dynabeads (Invitrogen) were added according to 
manufacturer’s instruction, and the iNOS inhibitor, L-NMMA (Sigma), was added at 0.5 mM 
where indicated. After 48 hours, T cell proliferation was evaluated on a BD LSRII flow 
cytometer using Diva software using the following antibodies: CD8a-PE (1:600; clone 53-6.7), 
CD11b-APC (1:400; clone M1/70), Ly6C-eFluor 450 (1:400; clone HK1.4), Ly6G-AlexaFluor 
700 (1:400; clone 1A8) and 7AAD viability marker. Data analyses were performed using 
FlowJo Software version 9.7.1. Proliferation index was calculated using the formula, (% of 
proliferated, co-cultured CD8+ T cells) ÷ (% of proliferated CD8+ T cells without co-culture) x 
100, for each replicate experiment.  
 
Cytokine analysis 
Multiplex quantification of cytokines and chemokines in mammary glands and tumors was 
performed using the premixed 24-plex Bio-Plex Pro Mouse Cytokine Assay (Bio-Rad) 
according to manufacturer’s recommendations. Proteins lysates were prepared as previously 
described31. Unsupervised clustering was performed on normalized, median centered data 
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then converted to a heat-map using Genesis software. For IL17A and G-CSF serum levels, 
BD Cytometric Bead Arrays were used as directed and analyzed on a Cyan flow cytometer 
with Summit software (Beckman Coulter). Data analyses were performed using FlowJo 
Software version 9.7.1. For TGFβ1, a DuoSet ELISA kit was purchased from R&D Systems 
and performed according to the manufacturer’s instructions. 
 
PCR array 
The spleens of three wild-type or K14cre;CdhF/F;Trp53F/F mammary tumor-bearing mice were 
pooled and labeled with anti-CD3 antibodies. CD3+ T cells were sorted using a BD FACSAria 
II. RNA was isolated with Trizol as above. Gene expression differences were analyzed using 
a mouse T cell-specific PCR array from Qiagen according to their instructions and software. 
Genes exhibiting a three-fold change were considered biologically relevant. 
 
Statistical analysis 
Data analyses were performed using GraphPad Prism version 7. Applied analyses are 
indicated in corresponding legends. Sample sizes were based on previous experience with 
the models9,31,33. Differences with a p < 0.05 were considered statistically significant. 
 
EXTENDED DATA FIGURE LEGENDS 
Extended Data Figure 1. Systemic neutrophil expansion and accumulation in 
mammary tumor-bearing K14cre;Cdh1F/F;Trp53F/F (KEP) mice and the metastasis 
model. a, Representative images of neutrophils identified by the 7/4 antibody in lung 
sections in wild-type (WT) or KEP mice. Scale bar = 50 µm. b, Quantification of neutrophil 
accumulation per field of view (FOV) in various organs by immunohistochemistry using the 
7/4 antibody (n = 6 WT, 9 KEP mice). c, Absolute neutrophil counts in blood of WT and 
tumor-bearing KEP mice (n = 4 WT, 8 KEP). d, Quantification of neutrophil accumulation in 
various organs determined by flow cytometry and gated on CD45+ cells. Neutrophils were not 
detectable in WT mammary glands (n = 5 WT, 7 KEP mice). e, Representative images of 
Ly6G-stained lung sections and quantification of neutrophil accumulation in the metastasis 
model. Data were generated from mock-transplanted, non-tumor-bearing mice (0 mm2), or 
tumor-transplanted recipient mice sacrificed when tumors reached the tumor size shown or 
when mice exhibited signs of respiratory distress due to pulmonary metastasis. For 
quantification in lungs with metastases, neutrophils residing inside metastases were 
excluded. T = pulmonary metastatic lesion. Scale bar = 100 µm (n = 3, 5, 6, 6 and 3 mice for 
0, 9, 25, 100 mm2 and metastasis respectively). f, Kinetics of neutrophil accumulation in 
various organs of the metastasis model by flow cytometry after gating on CD45+ cells. 
Recipient mice transplanted with KEP tumor pieces were sacrificed at the tumor size shown 
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(n = 6, 5, 6, and 7 mice for 0, 9, 25, 100 mm2 respectively). g, Kinetics of neutrophil 
proportions in blood (gated on CD45+ cells), before and after surgical removal of their 
primary tumor (n = 5). All data are mean + s.e.m. *p<0.05, **p<0.01, ***p<0.001 as 
determined by Mann-Whitney U test or Kruskal–Wallis test followed by Dunn’s post test. 
 
Extended Data Figure 2. Neutrophil depletion does not affect primary tumor or 
metastatic nodule growth. a, Schematic illustration of the neutrophil depletion experiment 
in the spontaneous metastasis model. b, Representative dot plots of neutrophils gated on 
CD45+ cells in blood of control and anti-Ly6G-treated recipient mice. The Gr1 antibody was 
used here to avoid false negative results since the anti-Ly6G depleting antibody may mask 
the Ly6G epitope. CD11b+Gr1high cells were Ly6C+CCR2—, indicating that these cells were 
neutrophils. CD11b+Gr1low cells that were Ly6C+ and CCR2+ represented the monocytic 
fraction. c, Quantification of neutrophil depletion in blood of control and anti-Ly6G-treated 
recipient mice at the tumor size indicated (n = 8 control, 5 anti-Ly6G; **p<0.01 as determined 
by Mann-Whitney U test). d, Primary tumor growth kinetics of mice treated as indicated (n = 
12 control, 14 anti-Ly6G ). e, Representative images of primary tumors in the metastasis 
model treated as shown and stained with H&E, cytokeratin 8, vimentin, E-cadherin and CD34. 
Scale bar = 100 µm. f, Quantification of blood vessels per field of view (FOV) in control and 
neutrophil-depleted mice by anti-CD34 immunohistochemistry (n = 10). g, Quantification of 
pulmonary metastatic nodule size in control and neutrophil-depleted mice (n = 9 control, 11 
early phase, 14 late phase mice). All data are mean + s.e.m. 
 
Extended Data Figure 3. Subpopulations of neutrophils in mammary tumor-bearing 
mice are immature. a, Gating strategy for identification of neutrophils 
(CD45+CD11b+Ly6G+Ly6C+F4/80— cells), cKIT+ neutrophils and monocytes 
(CD45+CD11b+Ly6G—Ly6C+F4/80— cells) by flow cytometry. Blood cells from WT and tumor-
bearing KEP mice are shown here. b, Quantification of cKIT+ neutrophil accumulation in 
various organs determined by flow cytometry after gating on 
CD45+CD11b+Ly6G+Ly6C+F4/80— cells. cKIT+ neutrophils were not detectable in WT 
mammary glands (n = 5 WT, 7 KEP; Mann-Whitney U test). c, cKIT+ neutrophil proportions in 
various organs of the metastasis model as determined by flow cytometry after gating on 
CD45+CD11b+Ly6G+Ly6C+F4/80— cells. Mice were sacrificed at the tumor size shown (n = 5, 
5, 5, and 8 mice for 0, 9, 25, 100 mm2 respectively; Kruskal–Wallis test followed by Dunn’s 
post test). d, Kinetics of cKIT+ neutrophil proportions in blood (gated on 
CD45+CD11b+Ly6G+Ly6C+F4/80— cells), before and after surgical removal of their primary 
tumor (n = 5/group; Mann-Whitney U test). e, Representative images and quantification of 
neutrophil nuclear morphology. Ly6G+ cells were isolated from blood of WT and tumor-
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bearing KEP mice then assessed by Giemsa stain. Hyper-segmented cells were considered 
mature, whereas all other cells were considered immature. Scale bar = 10 µm.  (n = 6 WT, 5 
KEP mice; Mann-Whitney U test). All data are mean + s.e.m. *p<0.05, **p<0.01, ***p<0.001.  
 
Extended Data Figure 4. Neutrophils influence the function and phenotype of CD8+ T 
cells. a, Unsupervised hierarchical clustering of RNA-Seq analysis depicting 100 
differentially expressed genes between circulating neutrophils from WT and tumor-bearing 
KEP mice . P value (0.05) was used as cutoff (n = 4 WT, 5 KEP mice). See also Extended 
Data Table 1 for top 50 genes ranked by fold change. b, Circulating neutrophils from either 
WT or tumor-bearing KEP mice were incubated with CFSE-labeled splenic CD8+ T cells from 
WT mice and CD3/CD28 stimulation beads. The iNOS inhibitor, L-NMMA, was added where 
indicated. After 48 hours, CD8+ T cell proliferation was measured by flow cytometry. c, Dot 
plots depicting live cell-gated CD8+ T cell proportions in lungs of mice in control and 
neutrophil-depleted mice, sacrificed when transplanted tumors reached 100 mm2. d, Dot 
plots of effector CD8+ T cell (CD62L—CD44+) proportions in lungs of transplanted mammary 
tumor-bearing mice that were sacrificed when tumors reached 100 mm2. e, IFNγ expression 
by CD8+ T cells in lungs of transplanted mammary tumor-bearing mice that were sacrificed 
when tumors reached 100 mm2. f, Tumor growth kinetics in neutrophil-depleted or combined 
neutrophil- and CD8+ T cell-depleted, mammary tumor-transplanted recipient mice, as 
compared with control (n = 13 control, 21 anti-Ly6G, 14 anti-Ly6G/CD8). Data are mean + 
s.e.m. 
 
Extended Data Figure 5. Cytokine expression levels in tumors and T cells, and their 
effects on neutrophils. a, Unsupervised clustering of cytokine expression analysis in WT 
mammary glands and KEP tumors. Protein lysates were prepared as previously described 
from whole tissue31 and analyzed for expression of various cytokines by Luminex-based 
assay (n = 5/group). b, Protein levels of indicated cytokines in WT mammary glands and 
KEP tumors, determined by Luminex-based cytokine profiling. n.d. = not detectable (n = 
10/group; Mann-Whitney U test). c, d, Quantification of neutrophil and cKIT-expressing 
neutrophil accumulation in blood as determined by flow cytometry and gated on CD45+ cells. 
WT (n = 4) or tumor-bearing KEP mice (n = 9) were treated with anti-IL17 (n = 8) and/or 
recombinant G-CSF (rG-CSF; n = 4) where indicated (Mann-Whitney U test or Kruskal–
Wallis test followed by Dunn’s post test). e, Gene expression in circulating neutrophils from 
WT control (n = 5), rG-CSF-treated WT mice (n = 4), KEP control (n = 10), anti-IL17-treated 
(n = 6), anti-IL17 + rG-CSF-treated KEP mice (n = 4; Mann-Whitney U test or Kruskal–Wallis 
test followed by Dunn’s post test). f, Spleens of three WT mice and three KEP mice were 
pooled and CD3+ T cells were isolated. These cells were analyzed by a real-time PCR array 
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containing 86 different genes. Gene expression changes of greater than three-fold are shown. 
Members of the IL17 signaling pathway are depicted in blue. *p<0.05, **p<0.01, ***p<0.001. 
All data are mean + s.e.m.  
 
Extended Data Figure 6. Absence of the adaptive immune system reduces metastasis. 
a, Graphic representation of mammary tumor latency (left panel) and tumor growth (right 
panel) in lymphocyte-proficient KEP;Rag1+/—  and lymphocyte-deficient KEP;Rag1—/—  mice 
(n = 30/group). b, Levels of TGFβ1 in mammary tumors and the plasma of tumor-bearing 
mice (n = 6 tumor, 3 plasma). c, Quantification of metastatic burden in lungs of recipient WT  
or Rag1—/— mice that were transplanted with KEP mammary tumor fragments and underwent 
surgical removal of the primary tumor (n = 6 WT, 4 Rag1—/—  mice; **p<0.01, Mann-Whitney 
U test). Data are mean + s.e.m. 
 
 
Extended Data Figure 7. Depletion of CD4+ T cells does not affect systemic cytokine 
levels or neutrophil expansion. a, The proportion of IL17A+ cells among CD4+ T cells in 
organs of wild-type (WT) and tumor-bearing K14cre;Cdh1F/F;Trp53F/F (KEP) mice (n = 
6/group; Mann-Whitney U test). b, Median fluorescence intensity (MFI) of IL17A expression 
in circulating γδ and CD4+ T cells from tumor-bearing KEP mice, as determined by flow 
cytometry (n = 11/group; Wilcoxon matched-pairs test). c, Representative dot plots depicting 
total neutrophil and cKIT+ proportions in blood of control, anti-CD4- and anti-γδTCR-treated 
tumor-bearing KEP mice. d, Quantification of total neutrophil and cKIT+ neutrophil 
proportions in blood of control and anti-CD4-treated  tumor-bearing KEP mice (n = 7/group; 
Mann-Whitney U test). e, Serum levels of IL17A and G-CSF in control and anti-CD4-treated 
tumor-bearing KEP mice (n = 10 control, 6 anti-CD4; Mann-Whitney U test). *p<0.05, 
**p<0.01. All data are mean + s.e.m.  
 
Extended Data Figure 8. γδ T cell phenotype in KEP mice and their lack of influence on 
tumor growth in the metastasis model. a, γδ T cells from lungs of tumor-bearing KEP mice 
were analyzed by flow cytometry for IL17, CD27, Vγ1, and Vγ4 expression. Two major 
populations of γδ T cells were observed including IL17+CD27— and IL17—CD27+ cells. b, 
Representative histograms of CCR6, IL1R1, IL23R and RORγt expression in IL17+CD27— 
and IL17—CD27+ γδ T cell populations shown in a. c, Il1β gene expression in various cell 
populations isolated from transplanted KEP tumors. Tumors from three mice were pooled to 
form one group. CD45— cells (which includes cancer cells, endothelial cells and fibroblasts), 
CD45+CD11b+F4/80+ macrophages, CD45+CD11b+Ly6G+ neutrophils and CD45+CD11b— 
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lymphocytes were sorted from two pooled groups. Real time-PCR was performed on 
individual cell populations for Il1β expression. Relative expression among different cells is 
shown. d, Graphic representation of immune cell proportions in KEP tumors (n = 4). e, 
Primary tumor growth kinetics of control and γδ T cell-depleted tumor transplant recipient 
mice (n = 13/group). f, Growth kinetics of primary tumors transplanted into Tcrδ+/— (n = 10) 
and Tcrδ—/— mice (n = 6). All data are mean + s.e.m. 
 
Extended Data Figure 9. The γδ T cell-IL17-neutrophil axis promotes metastatic breast 
cancer. Mammary tumors evoke a systemic inflammatory cascade that is initiated by IL1β 
production. Tumor-derived IL1β activates γδ T cells to produce IL17. Increased systemic IL17 
levels lead to upregulation of G-CSF, which subsequently causes neutrophil expansion and 
alteration of neutrophil phenotype. These phenotypically altered neutrophils produce iNOS 
that suppresses the activity of anti-tumor CD8+ T cells. As a result of this systemic 
inflammatory cascade, the chance that disseminated cancer cells can establish metastases 
in distant organs is maximized. 
 
Extended Data Table 1. The top 50 most differentially expressed genes between 
neutrophils from WT and KEP mice. 
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